From Natural to Artificial Antitumor Lipidic Alkynylcarbinols: Asymmetric Synthesis, Enzymatic Resolution, and Refined SARs

Dymytrii Listunov; Etienne Joly; Pauline Rullière; Hafida Gaspard; Vania Bernardes-Génisson; Yves Génisson; Valérie Maraval; Remi Chauvin

doi:10.1055/s-0037-1610006

Synthesis, Table of Contents

Synthesis 2018; 50(16): 3114-3130
DOI: 10.1055/s-0037-1610006

short review

From Natural to Artificial Antitumor Lipidic Alkynylcarbinols: Asymmetric Synthesis, Enzymatic Resolution, and Refined SARs

Dymytrii Listunov

^aCNRS, LCC (Laboratoire de Chimie de Coordination), 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France Email: valerie.maraval@lcc-toulouse.fr Email: chauvin@lcc-toulouse.fr

^bUniversité de Toulouse, UPS, ICT-FR 2599, 31062 Toulouse Cedex 9, France

,

Etienne Joly

^cUMR CNRS 5089, IPBS (Institut de Pharmacologie et de Biologie Structurale), 205 Route de Narbonne, 31077 Toulouse Cedex 4, France

,

Pauline Rullière

^dUMR CNRS 5068, LSPCMIB, Université de Toulouse, Université Paul Sabatier, 118 Route de Narbonne, 31062 Toulouse Cedex 9, France Email: genisson@chimie.ups-tlse.fr

,

Hafida Gaspard

^dUMR CNRS 5068, LSPCMIB, Université de Toulouse, Université Paul Sabatier, 118 Route de Narbonne, 31062 Toulouse Cedex 9, France Email: genisson@chimie.ups-tlse.fr

,

Vania Bernardes-Génisson

^aCNRS, LCC (Laboratoire de Chimie de Coordination), 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France Email: valerie.maraval@lcc-toulouse.fr Email: chauvin@lcc-toulouse.fr

^bUniversité de Toulouse, UPS, ICT-FR 2599, 31062 Toulouse Cedex 9, France

,

Yves Génisson*

^dUMR CNRS 5068, LSPCMIB, Université de Toulouse, Université Paul Sabatier, 118 Route de Narbonne, 31062 Toulouse Cedex 9, France Email: genisson@chimie.ups-tlse.fr

,

Valérie Maraval*

^aCNRS, LCC (Laboratoire de Chimie de Coordination), 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France Email: valerie.maraval@lcc-toulouse.fr Email: chauvin@lcc-toulouse.fr

^bUniversité de Toulouse, UPS, ICT-FR 2599, 31062 Toulouse Cedex 9, France

,

Remi Chauvin *

^aCNRS, LCC (Laboratoire de Chimie de Coordination), 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France Email: valerie.maraval@lcc-toulouse.fr Email: chauvin@lcc-toulouse.fr

^bUniversité de Toulouse, UPS, ICT-FR 2599, 31062 Toulouse Cedex 9, France

› Author Affiliations

Abstract

All articles of this category

Abstract

Among acetylenic natural products, chiral lipidic alkynylcarbinol (LAC) metabolites, mostly extracted from marine sponges, have revealed a broad spectrum of biological activities, in particular, remarkable antitumor cytotoxicity. With reference to one of the simplest natural representatives, [(S)-eicos-(4E)-en-1-yn-3-ol], and a given cancer cell line (HCT116), combined extensive efforts in chemical synthesis (relying on the use of a large chemical toolbox) and biological analysis (in vitro tests), have provided systematic structure–activity relationships (SARs) where the initially selected four structural parameters appear as independent principal components: (i) and (ii) the sp/sp² content and extent of the terminal and internal unsaturations adjacent to the carbinol center, (iii) the absolute configuration of the latter, (iv) the length of the n-aliphatic backbone. Two key criteria have also been established regarding the functional alkynylcarbinol pharmacophore: the alkynylcarbinol unit must be both secondary and terminal (i.e., substituted by a short ethynyl or ethenyl C₂ group). This review is intended to provide a further illustration of the value of a simple rational approach for drug design, and to act as a benchmark for future optimization of LACs as antitumor agents.

1 Introduction

2 2C₂-Unsaturated Pharmacophore Candidates

2.1 Alkenylalkynylcarbinols (AACs)

2.2 Dialkynylcarbinols (DACs or DACys)

2.3 Alkynylalkenylcarbinols (iso-AACs) and Dialkenylcarbinols (DACes)

2.4 Oxidation-Protected Dialkynylcarbinols and Dialkynylketones

2.5 Fluorophore-Labeled Lipidic Dialkynylcarbinols

3 C₂/C₃-Unsaturated Pharmacophore Candidates

3.1 Cyclopropylalkynylcarbinols (CACs)

3.2 Allenylalkynylcarbinols (AllACs)

4 C₂/C₄- and 3C₂-Unsaturated Pharmacophore Candidates

4.1 Butadiynylalkynylcarbinols (BACs)

4.2 Trialkynylcarbinols (TACs)

5 Double-AC-Headed Pharmacophore Candidates

6 Screening on the Lipidic Chain Length

7 Conclusion

Key words

alkynes - asymmetric synthesis - antitumor cytotoxicity - chiral propargylic alcohols - lipidic alkynylcarbinols - marine drugs - stereoselectivity - structure–activity relationships

Full Text

References

References
1 Current address: Department of Pathology, Michigan University, 1500 E. Medical Center, Ann Arbor, MI 48109-5054, USA.
2 Listunov D. Maraval V. Chauvin R. Génisson Y. Nat. Prod. Rep. 2015; 32: 49
3 Gunasekera SP. Faircloth GT. J. Org. Chem. 1990; 55: 6223
4 Hallock YF. Cardellina JH. Balaschak MS. Alexander MR. Prather TR. Shoemaker RH. Boyd MR. J. Nat. Prod. 1995; 58: 1801
5 Fusetani N. Shiragaki T. Matsunaga S. Hashimoto K. Tetrahedron Lett. 1987; 28: 4313

6a Higa T. Tanaka J. Kitamura A. Koyama T. Takahashi M. Uchida T. Pure Appl. Chem. 1994; 66: 2227
6b Kobayashi M. Mahmud T. Tajima H. Wang WQ. Aoki S. Nakagawa S. Mayumi T. Kitagawa I. Chem. Pharm. Bull. 1996; 44: 720

7 Seo Y. Cho KW. Rho JR. Shin J. Sim CJ. Tetrahedron 1998; 54: 447

See for examples:

8a Isaacs S. Kashman Y. Loya S. Hizi A. Loya Y. Tetrahedron 1993; 49: 10435
8b Kim DK. Lee MY. Lee DS. Lee JR. Lee BJ. Jung JH. Cancer Lett. 2002; 185: 95
8c Hong SY. Kim SH. Rhee MH. Kim AR. Jung JH. Chun T. Yoo ES. Cho JY. Naunyn-Schmeideberg’s Arch. Pharmacol. 2003; 368: 448
8d Lee HS. Lee JH. Won H. Park SK. Kim HM. Shin HJ. Park HS. Sim CJ. Kim HK. Lipids 2009; 44: 71

9 Sharma A. Chattopadhyay S. Tetrahedron: Asymmetry 1998; 9: 2635
10 Gung BW. Dickson HD. Seggerson S. Bluhm K. Synth. Commun. 2002; 32: 2733
11 Garcia J. Lopez M. Romeu J. Tetrahedron: Asymmetry 1999; 10: 2617
12 Li ZY. Wang M. Bian QH. Zheng B. Mao JY. Li SN. Liu SZ. Wang MA. Zhong JC. Guo HC. Chem. Eur. J. 2011; 17: 5782
13 Trost BM. Weiss AH. Org. Lett. 2006; 8: 4461

14a Curran DP. Sui B. J. Am. Chem. Soc. 2009; 131: 5411
14b Sui B. Yeh EA. H. Vurran DP. J. Org. Chem. 2010; 75: 2942

15a Frantz DE. Fassler R. Carreira EM. J. Am. Chem. Soc. 2000; 122: 1806
15b Frantz DE. Fassler R. Tomooka CS. Carreira EM. Acc. Chem. Res. 2000; 33: 373

16 Kirkhman JE. D. Courteny TD. L. Lee V. Baldwin JE. Tetrahedron 2005; 61: 7219
17 Li M. Zou C. Duhayon C. Chauvin R. Tetrahedron Lett. 2006; 47: 1047

18a Moore D. Pu L. Org. Lett. 2002; 4: 1855
18b Gao G. Moore D. Xie RG. Pu L. Org. Lett. 2002; 4: 4143
18c Pu L. Acc. Chem. Res. 2014; 47: 1523

19 Trost BM. Weiss AH. Jacobi von Wangelin A. J. Am. Chem. Soc. 2006; 128: 8
20 El Arfaoui D. Listunov D. Fabing I. Oukessou M. Frongia C. Lobjois V. Samson A. Ausseil F. Ben-Tama A. El Hadrami EM. Chauvin R. Génisson Y. ChemMedChem 2013; 8: 1779

For natural product isolation, see:

21a Aoki S. Matsui K. Wei H. Murakami N. Kobayashi M. Tetrahedron 2002; 58: 5417
21b For biological studies, see: Izumi M. Yogosawa S. Aoki S. Watanabe H. Kamiyama J. Takahara Y. Sowa Y. Kobayashi M. Hosoi H. Sugimoto T. Sakai T. Int. J. Oncol. 2006; 29: 169
21c For synthetic studies, see: Dzhemileva LU. D’yakonov VA. Makarov AA. Andreev EN. Yunusbaeva MM. Dzhemilev UM. Org. Biomol. Chem. 2017; 15: 470

22 Haack KJ. Hashiguchi S. Fujii A. Ikariya T. Noyori R. Angew. Chem. Int. Ed. 1997; 36: 285

23a Matsumura K. Hashiguchi S. Ikariya T. Noyori R. J. Am. Chem. Soc. 1997; 119: 8738
23b Noyori R. Kitamura M. Angew. Chem. Int. Ed. 1991; 30: 49

24 Listunov D. Billot C. Joly E. Fabing I. Volovenko Y. Génisson Y. Maraval V. Chauvin R. Tetrahedron 2015; 71: 7920
25 Dembitsky VM. Lipids 2006; 41: 883
26 Kim JS. Lim YJ. Im KS. Jung JH. Shim CJ. Lee CO. Hong J. Lee H. J. Nat. Prod. 1999; 62: 554
27 Takanashi E. Takada K. Hashimoto M. Itoh Y. Ise Y. Ohtsuka S. Okada S. Matsunaga S. Tetrahedron 2015; 71: 9564
28 Nuzzo G. Ciavatta ML. Villani G. Manzo E. Zanfardino A. Varcamonti M. Gavagnin M. Tetrahedron 2012; 68: 754

29a Shin JH. Seao YW. Cho KW. Rho JR. Paul VJ. Tetrahedron 1998; 54: 8711
29b Shin J. See Y. Cho KW. Rho JR. Paul VJ. Tetrahedron 1998; 54: 14636

30 Chill L. Miroz A. Kashman Y. J. Nat. Prod. 2000; 63: 523
31 Zhou G.-X. Molinski TF. Mar. Drugs 2003; 1: 46
32 Rullière P., Lizeaux F., Joly E., Gaspard H., Maraval V., Chauvin R., Génisson Y.; submitted for publication.

For dideoxypetrosynol A, see:

33a Choi HJ. Bae SJ. Kim ND. Jung JH. Choi YH. Int. J. Mol. Med. 2004; 14: 1091
33b For petrotetrayndiol, see: Choi HJ. Yee SB. Park SE. Im E. Jung JH. Chung HY. Kim ND. Cancer Lett. 2006; 232: 214
33c For (3S)-eicos-(4E)-en-1-yn-3-ol, see: Zovko A. Viktorsson K. Haag P. Kovalerchick D. Farnegardh K. Alimonti A. Ilan M. Carmeli S. Lewensohn R. Mol. Cancer Ther. 2014; 13: 2941

34a Nickel S. Serwa RA. Kaschani F. Ninck S. Zweerink S. Tate EW. Maiser M. Chem. Eur. J. 2015; 21: 10721
34b Zovko A. Novak M. Hååg P. Kovalerchick D. Holmlund T. Färnegårdh K. Ilan M. Carmeli S. Lewensohn R. Viktorsson K. Oncotarget 2016; 7: 50258

35 Listunov D. Mazères S. Volovenko Y. Joly E. Génisson Y. Maraval V. Chauvin R. Bioorg. Med. Chem. Lett. 2015; 25: 4652
36 Sivakumar K. Xie F. Cash BM. Long S. Barnhill HN. Wang Q. Org. Lett. 2004; 6: 4603
37 Greenspan P. Mayer EP. Fowler SD. J. Cell. Biol. 1985; 100: 965
38 Gocze PM. Freeman DA. Cytometry 1994; 17: 151
39 Epshtein AE. Dolglii IE. Limanov VE. Skvortsova EK. Nefedov OM. Izv. Akad. Nauk. SSSR Ser. Khim. 1978; 2: 500 ; Russ. Chem. Bull. 1978, 27, 438
40 Hoffmann-Roder A. Krause N. Angew. Chem. Int. Ed. 2004; 43: 1196

41a de Graaf W. Smits A. Boersma J. van Koten G. Hoestra WP. Tetrahedron 1988; 44: 6699
41b Schlingmann G. Milne L. Pearce CJ. Borders DB. Greenstein M. Maise WM. Carter GT. J. Antibiot. 1995; 48: 375
41c For a review see: Nicolaou KC. Dai WM. Angew. Chem. Int. Ed. 1991; 30: 1387
41d Zhang Y. Wu Y. Org. Biomol. Chem. 2010; 10: 4744

42a Jones BC. N. M. Silverton JV. Simons C. Megati S. Nishimura H. Maeda Y. Mitsuya H. Zemlicka J. J. Med. Chem. 1995; 38: 1397
42b Megati S. Goren Z. Silverton JV. Orlina J. Nishimura H. Shirasaki T. Mitsuya H. Zemlicka J. J. Med. Chem. 1992; 35: 4098 ; Erratum: J. Med. Chem. 1993, 36, 634

43 Luo H. Ma S. Eur. J. Org. Chem. 2013; 3041
44 Listunov D., Joly E., Duhayon C., Saffon-Merceron N., Fabing I., Génisson Y., Maraval V., Chauvin R. ChemMedChem 2018, in press, DOI: 10.1002/cmdc.201800284.
45 Listunov D. Maraval V. Saffon-Merceron N. Mallet-Ladeira S. Voitenko Z. Volovenko Y. Génisson Y. Chauvin R. French-Ukr. J. Chem. 2015; 3: 21
46 Sharma A. Chattopadhyay S. J. Org. Chem. 1998; 63: 6128
47 Huang X. Cao T. Han Y. Jiang X. Lin W. Zhang J. Ma S. Chem.Commun. 2015; 51: 6956

48a Bohlmann F. Arndt C. Bornowski H. Kleine KM. Chem. Ber. 1961; 94: 958
48b Bohlmann F. Niedballa U. Rode K.-M. Chem. Ber. 1966; 99: 3552
48c Crosby DG. Aharonson N. Tetrahedron 1967; 23: 465
48d Bentley RK. Thaller V. Chem. Commun. (London) 1967; 439
48e Bentley RK. Bhattacharjee D. Jones ER. H. Thaller V. J. Chem. Soc. C 1969; 685
48f Yates SG. England RE. J. Agric. Food Chem. 1982; 30: 317

49 Kitagawa I. Yoshikawa M. Yoshihara M. Hayashi T. Taniyama T. Yakugaku Zasshi 1983; 103: 612

50a Zidorn C. Johrer K. Ganzera M. Schubert B. Sigmund EM. Mader J. Greil R. Ellmerer EP. Stuppner H. J. Agric. Food Chem. 2005; 53: 2518
50b Christensen LP. Recent Pat. Food Nutr. Agric. 2011; 3: 64

For reviews on the synthesis and biological activities of butadiyne- and polyyne-containing natural products, see ref. 23 and

50c Shi Shun AL. K. Tykwinski RR. Angew. Chem. Int. Ed. 2006; 45: 1034
50d Minto RE. Blacklock BJ. Prog. Lipid Res. 2008; 47: 233

51a Matsugana H. Katano M. Yamamoto H. Fujito H. Mori M. Takata K. Chem. Pharm. Bull. 1990; 38: 3480
51b Bernart MW. Cardellina JH. Balaschak MS. Alexander MR. Shoemaker RH. Boyd MR. J. Nat. Prod. 1996; 59: 748
51c Young JF. Duthie SJ. Milne L. Christensen LP. Duthie GG. Bestwick CS. J. Agric. Food Chem. 2007; 55: 618
51d Siddiq A. Dembitsky V. Anti-Cancer Agents Med. Chem. 2008; 8: 132
51e Yan Z. Yang R. Jiang Y. Yang J. Zhao Q. Lu Y. Molecules 2011; 16: 5561
51f Liang C. Ding Y. Kim JA. Yang SY. Boo H.-J. Kang H.-K. Nguyen MC. Kim YH. Bull. Korean Chem. Soc. 2011; 32: 3513

52 Heydenreuter W. Kunold E. Sieber SA. Chem. Commun. 2015; 15784

53a Zheng G. Lu W. Aisa HA. Cai J. Tetrahedron Lett. 1999; 40: 2181
53b McLaughlin NP. Butler E. Evans P. Brunton NP. Koidis A. Rai DK. Tetrahedron 2010; 66: 9681
53c Yang Y.-Q. Li S.-N. Zhong J.-C. Zhou Y. Zeng H.-Z. Duan H.-J. Bian Q.-H. Wang M. Tetrahedron: Asymmetry 2015; 26: 361

54 Listunov D. Saffon-Merceron N. Joly E. Fabing I. Génisson Y. Maraval V. Chauvin R. Tetrahedron 2016; 72: 6697
55 Matovic NJ. Hayes PY. Penman K. Lehmann RP. De Voss JJ. J. Org. Chem. 2011; 76: 4467
56 Nicolai S. Sedigh-Zadeh R. Waser J. J. Org. Chem. 2013; 78: 3783
57 Bourkhis M. Listunov D. Gaspard H. Joly E. Abderrahim R. Maraval V. Génisson Y. Chauvin R. French-Ukr. J. Chem. 2017; 5: 24
58 Detty MR. Luss HR. Organometallics 1992; 11: 2157
59 Fusetani N. Kato Y. Matsunaga S. Hashimoto K. Tetrahedron Lett. 1983; 24: 2771

60a Wright AE. McConnell OJ. Kohmoto S. Lui MS. Thompson W. Snader KM. Tetrahedron Lett. 1987; 28: 1377
60b Hitora Y. Takada K. Okada S. Ise Y. Matsunaga S. J. Nat. Prod. 2011; 74: 1262

61a Gung BW. Omollo AO. Eur. J. Org. Chem. 2008; 4790
61b Gung BW. C. R. Chim. 2009; 12: 489

62a Braekman JC. Daloze D. Devijver C. Dubut D. van Soest RW. M. J. Nat. Prod. 2003; 66: 871
62b Shirouzu T. Watari K. Ono M. Koizumi K. Saiki I. Tanaka C. van Soest RW. M. Miyamoto T. J. Nat. Prod. 2013; 76: 1337

63 Mori K. Akasaka K. Matsunaga S. Tetrahedron 2014; 70: 392
64 Listunov D. Fabing I. Saffon-Merceron N. Gaspard H. Volovenko Y. Maraval V. Chauvin R. Génisson Y. J. Org. Chem. 2015; 80: 5386
65 Bourkhis M. Gaspard H. Rullière P. de Almeida DK. C. Listunov D. Joly E. Abderrahim R. de Mattos MC. de Oliveira MC. F. Maraval V. Chauvin R. Génisson Y. ChemMedChem 2018; 13: 1124
66 Despite the occurrence of ambiguous definitions in the literature, the eudismic ratio increases with the relative potency of the eutomer, e.g., ER = IC₅₀(distomer)/IC₅₀(eutomer), as explicitly formulated in the following article: Talon S. De Luca A. De Bellis M. Desaphy J.-F. Lentini G. Scilimati A. Corbo F. Franchini C. Tortorella P. Jockusch H. Conte Camerino D. Br. J. Pharmacol. 2001; 134: 1523